Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT
| Autor: | Hilary A. Tindle, Stephen King, Matthew S. Freiberg, Robert A. Greevy, Quinn S. Wells, Rachel F. Tyndale, Suman Kundu, Lesa R. Abney, Elizabeth A. Scoville, Vanessa Gatskie, Meredith S. Duncan, Dawn B. Beaulieu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Nicotine medicine.medical_treatment Original Investigations Pilot Projects law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Tobacco Smoking Humans 030212 general & internal medicine Nicotinic Agonists Precision Medicine Varenicline Smoking Cessation Agents business.industry Public Health Environmental and Occupational Health Odds ratio Middle Aged Nicotine replacement therapy Confidence interval Tobacco Use Cessation Devices chemistry 030220 oncology & carcinogenesis Number needed to treat Smoking cessation Female Smoking Cessation business medicine.drug Follow-Up Studies |
| Popis: | INTRODUCTION: Varenicline doubles cessation over nicotine replacement therapy (NRT) patch for “normal,” but not “slow,” nicotine metabolizers, as assessed by the nicotine metabolite ratio (NMR). Metabolism-informed care (MIC) could improve outcomes by matching normal metabolizers with non-nicotine medication (e.g., varenicline) and slow metabolizers with NRT patch. METHODS: We conducted a feasibility randomized controlled trial of MIC versus guideline based care (GBC) among 81 outpatient adult daily smokers with medical comorbidity. Participants reported perceptions of MIC, underwent blood draw for NMR, and received expert cessation counseling. For MIC participants, medication selection was informed by NMR result (normal (≥0.31) vs. slow (< 0.31)). The primary outcome was MIC feasibility, reflected by attitudes toward MIC and by match rates between NMR and medication. Secondary endpoints (cessation confidence, medication use, smoking status) were assessed over 6 months to inform future studies. RESULTS: Participants were median age 53 years, 46% female, 28% black, and ~90% endorsed MIC. Despite high varenicline prescription rates (~60%) in both arms, NMR-medication matching was higher in MIC (84%) versus GBC (58%) participants (p=0.02); unadjusted odds ratio (OR) 3.67, 95% confidence interval [1.33, 11.00; p-value=0.02]. Secondary endpoints were similar at 1, 3, and 6 months. CONCLUSIONS: MIC, an NMR-based precision approach to smoking cessation, was acceptable to 90% of smokers and improved NMR-medication match rates more than 3-fold compared to GBC, even with generally high use of varenicline. These data support the feasibility of MIC, which could maximize efficacy of smoking cessation medication while minimizing side effects and cost. IMPLICATIONS: Among treatment-seeking daily smokers with medical comorbidity, most viewed metabolism-informed care (MIC), guided by the nicotine metabolism ratio (NMR), favorably, and were willing to accept MIC-guided medication. Compared to GBC participants (58%), more MIC participants (84%) were prescribed NMR-matched medication (i.e., normal metabolizers received varenicline; slow metabolizers received NRT patch). MIC increased the odds of optimized matching between NMR and medication more than 3-fold over GBC. Because the number needed to treat (NNT) to help one normal metabolizer quit smoking is only 4.9 for varenicline versus 26 for patch, broad implementation of MIC will improve drug efficacy in normal metabolizers as well as minimize side effects in slow metabolizers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|